[go: up one dir, main page]

SMT201200063B - Composti 4-[2-(-fluorofenossimetil)fenil]piperidinici - Google Patents

Composti 4-[2-(-fluorofenossimetil)fenil]piperidinici

Info

Publication number
SMT201200063B
SMT201200063B SM201200063T SM201200063T SMT201200063B SM T201200063 B SMT201200063 B SM T201200063B SM 201200063 T SM201200063 T SM 201200063T SM 201200063 T SM201200063 T SM 201200063T SM T201200063 B SMT201200063 B SM T201200063B
Authority
SM
San Marino
Prior art keywords
fluorophenoxymethyl
piperidines
phenyl
compounds
Prior art date
Application number
SM201200063T
Other languages
English (en)
Inventor
Lori Jean Patterson
Eric L Stangeland
Sheila Zipfel
Daniel D Long
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41666409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201200063(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of SMT201200063B publication Critical patent/SMT201200063B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
SM201200063T 2008-11-14 2012-12-27 Composti 4-[2-(-fluorofenossimetil)fenil]piperidinici SMT201200063B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11454108P 2008-11-14 2008-11-14
PCT/US2009/064308 WO2010056941A1 (en) 2008-11-14 2009-11-13 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

Publications (1)

Publication Number Publication Date
SMT201200063B true SMT201200063B (it) 2013-01-14

Family

ID=41666409

Family Applications (3)

Application Number Title Priority Date Filing Date
SM201200063T SMT201200063B (it) 2008-11-14 2012-12-27 Composti 4-[2-(-fluorofenossimetil)fenil]piperidinici
SM201200065T SMT201200065B (it) 2008-11-14 2012-12-28 Forma cristallina di un composto 4-[2-(2-fluorofenossimetil)fenil]piperidina
SM201300033T SMT201300033B (it) 2008-11-14 2013-03-26 Procedimento per preparare composti della 4-[2-(2-fluorofenossimetil)fenil]piperidina

Family Applications After (2)

Application Number Title Priority Date Filing Date
SM201200065T SMT201200065B (it) 2008-11-14 2012-12-28 Forma cristallina di un composto 4-[2-(2-fluorofenossimetil)fenil]piperidina
SM201300033T SMT201300033B (it) 2008-11-14 2013-03-26 Procedimento per preparare composti della 4-[2-(2-fluorofenossimetil)fenil]piperidina

Country Status (28)

Country Link
US (23) US8304432B2 (it)
EP (3) EP2358675B9 (it)
JP (6) JP5598798B2 (it)
KR (3) KR101656338B1 (it)
CN (3) CN102216272B (it)
AR (3) AR074350A1 (it)
AU (3) AU2009313949B2 (it)
BR (3) BRPI0921593B8 (it)
CA (3) CA2742105C (it)
CL (2) CL2011001088A1 (it)
CO (2) CO6361988A2 (it)
CY (3) CY1113622T1 (it)
DK (3) DK2358676T3 (it)
ES (3) ES2397247T3 (it)
HR (3) HRP20120897T1 (it)
IL (2) IL212230A (it)
MX (3) MX2011005088A (it)
MY (2) MY151211A (it)
NZ (2) NZ592543A (it)
PL (3) PL2358674T3 (it)
PT (3) PT2358676E (it)
RU (2) RU2515612C2 (it)
SG (1) SG171311A1 (it)
SI (3) SI2358676T1 (it)
SM (3) SMT201200063B (it)
TW (3) TWI461407B (it)
WO (3) WO2010056941A1 (it)
ZA (1) ZA201103495B (it)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2358676T3 (da) * 2008-11-14 2013-01-14 Theravance Inc Krystallinsk form af en 4-[2-(2-fluorphenoxymethyl)phenyl]-piperidinforbindelse
JP5705239B2 (ja) 2010-01-11 2015-04-22 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー セロトニンおよびノルエピネフリン再取込みインヒビターとしての１−（２−フェノキシメチルフェニル）ピペラジン化合物
US8530663B2 (en) * 2010-03-22 2013-09-10 Theravance, Inc. 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
JP5774091B2 (ja) * 2010-04-22 2015-09-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 疼痛治療のためのセロトニン・ノルエピネフリン再取り込みインヒビターとオピオイド作動物質との組み合わせ
CA2830882C (en) 2011-03-22 2021-03-16 Dinesh Barawkar Substituted fused tricyclic compounds, compositions and medicinal applications thereof
US9544692B2 (en) * 2012-11-19 2017-01-10 Bitwave Pte Ltd. System and apparatus for boomless-microphone construction for wireless helmet communicator with siren signal detection and classification capability
US10238642B2 (en) * 2016-08-30 2019-03-26 Theravance Biopharma R&D Ip, Llc Methods for treating neurogenic orthostatic hypotension
ES2960492T3 (es) 2018-06-01 2024-03-05 Theravance Biopharma R&D Ip Llc Procedimiento para la preparación de ácido 2-(1-(terc-butoxicarbonil)piperidín-4-il)benzoico
CA3252091A1 (en) 2022-03-28 2023-10-05 Theravance Biopharma R&D Ip, Llc Ampreloxetine is intended for use in the treatment of multiple system atrophy.
CN114957098B (zh) * 2022-06-02 2024-03-29 和鼎（南京）医药技术有限公司 一种制备喷他佐辛中间体的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE2549999A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
EP0190496A3 (en) 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
DE3835291A1 (de) * 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9324018D0 (en) * 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
BR9912013A (pt) * 1998-07-10 2001-04-10 Astrazeneca Ab Composto, composição farmacêutica, método de tratar uma condição de doença, e, processo para preparar um composto
GB9922521D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
NZ514403A (en) * 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
US6630504B2 (en) * 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US7294637B2 (en) * 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
ES2315525T3 (es) * 2002-08-23 2009-04-01 Eli Lilly And Company Derivados de 2-(feniltiometil)-morfolina para uso como inhibidores selectivos de la recaptacion de norepinefrina.
CL2004000726A1 (es) * 2003-04-04 2005-05-20 Lundbeck & Co As H Compuestos derivados de 4-[2-(feniloxi sustituido)fenil]piperidina o -1,2,3,6-tetrahidropiridina; composcion farmaceutica que los contiene; y su uso para el tratamiento de trastornos afectivos, tales como la depresion, trastornos de ansiedad, de ansi
HRP20080262T3 (hr) * 2003-04-04 2009-04-30 H. Lundbeck A/S Derivati 4-(2-feniloksifenil)-piperidin ili -1,2,3,6 tetrahidropiridin kao inhibitori ponovne apsorpcije serotonina
KR100803796B1 (ko) * 2003-06-17 2008-02-14 화이자 인코포레이티드 세로토닌 및 노르아드레날린 재흡수 억제제로서의ｎ-피롤리딘-3-일-아미드 유도체
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
BRPI0506844A (pt) * 2004-01-13 2007-06-12 Pfizer derivados de piperazina que apresentam atividade como inibidores da reabsorção de serotonina noradrenalina
US20070072859A1 (en) * 2004-03-05 2007-03-29 Eli Lilly And Company Pharmaceutical compounds
CA2564994A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
GB0505437D0 (en) * 2005-03-17 2005-04-20 Merck Sharp & Dohme Therapeutic agents
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
US20070249607A1 (en) * 2006-04-17 2007-10-25 Bristol-Myers Squibb Company Nk-1 and serotonin transporter inhibitors
US20100120858A1 (en) 2006-08-23 2010-05-13 Pfizer Inc. Piperidine Derivatives
WO2008039418A2 (en) * 2006-09-27 2008-04-03 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor modulators
US8026257B2 (en) * 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
CN102203074A (zh) 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 芳基gpr119激动剂及其用途
JP5405571B2 (ja) 2008-07-24 2014-02-05 セラヴァンス， インコーポレーテッド ３−（フェノキシフェニルメチル）ピロリジン化合物
DK2358676T3 (da) 2008-11-14 2013-01-14 Theravance Inc Krystallinsk form af en 4-[2-(2-fluorphenoxymethyl)phenyl]-piperidinforbindelse
JP5705239B2 (ja) 2010-01-11 2015-04-22 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー セロトニンおよびノルエピネフリン再取込みインヒビターとしての１−（２−フェノキシメチルフェニル）ピペラジン化合物
US8530663B2 (en) * 2010-03-22 2013-09-10 Theravance, Inc. 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
US10238642B2 (en) * 2016-08-30 2019-03-26 Theravance Biopharma R&D Ip, Llc Methods for treating neurogenic orthostatic hypotension

Also Published As

Publication number Publication date
EP2358675A1 (en) 2011-08-24
HK1160452A1 (en) 2012-08-17
BRPI0921593B1 (pt) 2021-05-04
US8304432B2 (en) 2012-11-06
BRPI0921595B8 (pt) 2021-05-25
TW201024264A (en) 2010-07-01
CN102216272B (zh) 2014-02-05
JP2014101384A (ja) 2014-06-05
IL212452A0 (en) 2011-06-30
DK2358676T3 (da) 2013-01-14
US20140057944A1 (en) 2014-02-27
PT2358676E (pt) 2012-12-06
AU2009313951B2 (en) 2015-03-12
KR20110082196A (ko) 2011-07-18
MX2011005089A (es) 2011-07-29
US20190134019A1 (en) 2019-05-09
US8304433B2 (en) 2012-11-06
HK1160448A1 (en) 2012-08-17
US20160022660A1 (en) 2016-01-28
RU2011123875A (ru) 2012-12-20
SI2358675T1 (sl) 2013-01-31
TW201022206A (en) 2010-06-16
EP2358676B1 (en) 2012-10-10
NZ592543A (en) 2013-02-22
MY151211A (en) 2014-04-30
US10946006B2 (en) 2021-03-16
US9187423B2 (en) 2015-11-17
JP5529150B2 (ja) 2014-06-25
JP2012508759A (ja) 2012-04-12
US10034870B2 (en) 2018-07-31
CN102209712B (zh) 2016-04-06
DK2358674T3 (da) 2013-04-08
JP5598798B2 (ja) 2014-10-01
US20180050024A1 (en) 2018-02-22
JP2014098033A (ja) 2014-05-29
NZ592413A (en) 2013-02-22
US20200316048A1 (en) 2020-10-08
DK2358675T3 (da) 2013-01-14
EP2358674B1 (en) 2013-01-02
CN102209712A (zh) 2011-10-05
US20130030185A1 (en) 2013-01-31
US11596624B2 (en) 2023-03-07
BRPI0921593B8 (pt) 2021-05-25
US10576073B2 (en) 2020-03-03
US12239638B2 (en) 2025-03-04
SI2358676T1 (sl) 2013-01-31
US10226454B2 (en) 2019-03-12
EP2358676A1 (en) 2011-08-24
CN102216272A (zh) 2011-10-12
TWI441810B (zh) 2014-06-21
US9162982B2 (en) 2015-10-20
KR20110082085A (ko) 2011-07-15
US8592596B2 (en) 2013-11-26
US20140323735A1 (en) 2014-10-30
MX2011005090A (es) 2011-09-06
RU2011123890A (ru) 2012-12-20
TWI461407B (zh) 2014-11-21
US20100125093A1 (en) 2010-05-20
HK1160449A1 (en) 2012-08-17
KR101656339B1 (ko) 2016-09-09
BRPI0921596A2 (pt) 2018-03-20
US20200316047A1 (en) 2020-10-08
KR101685186B1 (ko) 2016-12-09
US20140045892A1 (en) 2014-02-13
EP2358675B1 (en) 2012-10-03
CO6361993A2 (es) 2012-01-20
US20240316024A1 (en) 2024-09-26
US8247433B2 (en) 2012-08-21
ZA201103495B (en) 2012-01-25
PT2358675E (pt) 2012-12-12
HRP20120920T1 (hr) 2013-01-31
SG171311A1 (en) 2011-07-28
BRPI0921593A2 (pt) 2015-08-18
CL2011001088A1 (es) 2011-10-14
SI2358674T1 (sl) 2013-04-30
US20230201181A1 (en) 2023-06-29
SMT201300033B (it) 2013-05-06
JP5506813B2 (ja) 2014-05-28
WO2010056941A1 (en) 2010-05-20
HRP20120897T1 (hr) 2012-12-31
US9675599B2 (en) 2017-06-13
JP2012508761A (ja) 2012-04-12
US20130030020A1 (en) 2013-01-31
SMT201200065B (it) 2013-03-08
US11723900B2 (en) 2023-08-15
BRPI0921596B1 (pt) 2021-10-26
CN102216271A (zh) 2011-10-12
CY1113623T1 (el) 2016-06-22
US20200000792A1 (en) 2020-01-02
RU2515612C2 (ru) 2014-05-20
US20100125092A1 (en) 2010-05-20
US20210290608A1 (en) 2021-09-23
TWI443087B (zh) 2014-07-01
US10441579B2 (en) 2019-10-15
IL212230A (en) 2014-12-31
AU2009313949A1 (en) 2010-05-20
PL2358675T3 (pl) 2013-03-29
US20220087995A1 (en) 2022-03-24
WO2010056938A1 (en) 2010-05-20
HRP20130300T1 (hr) 2013-04-30
US20100125141A1 (en) 2010-05-20
KR101656338B1 (ko) 2016-09-09
CL2011001093A1 (es) 2011-09-02
US10206913B2 (en) 2019-02-19
US8802857B2 (en) 2014-08-12
EP2358675B9 (en) 2019-09-11
EP2358674A1 (en) 2011-08-24
ES2401224T3 (es) 2013-04-17
CY1113855T1 (el) 2016-07-27
CA2742114A1 (en) 2010-05-20
MX2011005088A (es) 2011-06-01
US10946007B2 (en) 2021-03-16
KR20110082197A (ko) 2011-07-18
AR074350A1 (es) 2011-01-12
AU2009313948A1 (en) 2010-05-20
AR114965A2 (es) 2020-11-11
US20120277438A1 (en) 2012-11-01
BRPI0921595B1 (pt) 2020-10-13
CY1113622T1 (el) 2016-06-22
AU2009313949B2 (en) 2015-03-19
PL2358676T3 (pl) 2013-03-29
CA2739992C (en) 2016-09-20
US20160184288A1 (en) 2016-06-30
ES2397247T3 (es) 2013-03-05
ES2396583T3 (es) 2013-02-22
CA2742105C (en) 2016-09-13
CN102216271B (zh) 2013-09-25
PL2358674T3 (pl) 2013-06-28
US20190142816A1 (en) 2019-05-16
MY151229A (en) 2014-04-30
WO2010056939A1 (en) 2010-05-20
CA2742105A1 (en) 2010-05-20
US20180289687A1 (en) 2018-10-11
US8604058B2 (en) 2013-12-10
JP2012508760A (ja) 2012-04-12
CA2742114C (en) 2016-09-13
AR074128A1 (es) 2010-12-22
CA2739992A1 (en) 2010-05-20
RU2503662C2 (ru) 2014-01-10
JP2014139209A (ja) 2014-07-31
TW201024263A (en) 2010-07-01
US10722504B2 (en) 2020-07-28
AU2009313951A1 (en) 2010-05-20
IL212230A0 (en) 2011-06-30
PT2358674E (pt) 2013-03-05
US9073859B2 (en) 2015-07-07
AU2009313948B2 (en) 2015-03-12
CO6361988A2 (es) 2012-01-20
US20180055830A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
SMT201200063B (it) Composti 4-[2-(-fluorofenossimetil)fenil]piperidinici
BRPI0817537A2 (pt) 4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona
RU2465270C3 (ru) Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она
DK2610258T3 (da) Substituerede piperidindihydrothienopyrimidiner
ATE506359T1 (de) Heteroaryl-substituierte piperidine
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt) compostos
DK2242759T3 (da) Forbindelser
BRPI0914775A2 (pt) compostos de fenila dissubstituídos
BRPI0906705A2 (pt) Composto heterocíclicos
BRPI0905874A2 (pt) Composição fotoprotetora
SMT201600045B (it) Composti tetraciclinici c7-fluoro sostituiti
BRPI0811264A2 (pt) Compostos
DK2297162T3 (da) Forbindelser
DK2308869T3 (da) Azolforbindelse
BR112012002336A2 (pt) compostos aza-heterocíclicos
BRPI0809996A2 (pt) Compostos
HRP20150932T1 (xx) Heterocikliäśki spojevi
BRPI0922098A2 (pt) composto inorgânicos
BRPI0916432A2 (pt) compostos
BRPI0923592A2 (pt) composto
DK2206698T3 (da) Ethynylindolforbindelser
BRPI0922152A2 (pt) Compostos
BRPI0818552A2 (pt) Piperidinas trissubstituídas
BRPI0913396A2 (pt) compostos de piperidina 3- ou 4-substituídos